Amoxicillin

Urinary Tract Infections, Sinusitis, Gonorrhea + 11 more
Treatment
2 FDA approvals
20 Active Studies for Amoxicillin

What is Amoxicillin

AmoxicillinThe Generic name of this drug
Treatment SummaryAmoxicillin, also known as BRL-2333, is a type of penicillin antibiotic. It was first introduced in 1972 and was approved by the FDA in 1974. Amoxicillin works similarly to penicillin and ampicillin, but it tends to stay in the bloodstream for a longer period of time.
Amoxicillinis the brand name
Amoxicillin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Amoxicillin
Amoxicillin
1978
1067

Approved as Treatment by the FDA

Amoxicillin, also called Amoxicillin, is approved by the FDA for 2 uses including Duodenal Ulcer and Duodenal ulcer caused by helicobacter pylori .
Duodenal Ulcer
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin
Duodenal ulcer caused by helicobacter pylori
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Effectiveness

How Amoxicillin Affects PatientsAmoxicillin works by stopping bacteria from forming their cell walls, which keeps them from reproducing. It has a long lasting effect when taken twice a day. It is generally safe even when taken in higher doses. However, patients should be aware of potential risks such as anaphylaxis, C. difficile infections, and antibiotic resistance.
How Amoxicillin works in the bodyAmoxicillin works by stopping certain proteins from helping bacteria build and repair their cell walls. Without these proteins, bacteria cannot properly build or repair the walls and eventually die.

When to interrupt dosage

The recommended measure of Amoxicillin is contingent upon the specified condition, such as Lower Respiratory Tract Infection (LRTI), Duodenal Ulcer and Stomach Ulcer. The amount of dosage differs, based on the administration approach (e.g. For suspension - Oral or Oral) as illustrated in the table below.
Condition
Dosage
Administration
Sinusitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Bronchitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Otitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Gonorrhea
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Duodenal Ulcer
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Bacterial Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Urinary Tract Infection (UTI)
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Peptic Ulcer With H. Pylori Infection
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Community Acquired Pneumonia (CAP)
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
ABDIC protocol
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
ear, nose, and throat infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Urinary Tract Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Urinary Tract Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release
Helicobacter Pylori Infection
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Powder, for suspension, Powder, for suspension - Oral, Kit, Suspension, Suspension - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, For suspension, For suspension - Oral, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension, Tablet, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release - Oral, Capsule, delayed release

Warnings

Amoxicillin Contraindications
Condition
Risk Level
Notes
Liver Dysfunction
Do Not Combine
Pulse Frequency
Do Not Combine
Jaundice, Obstructive
Do Not Combine
Jaundice, Obstructive
Do Not Combine
Liver Dysfunction
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Amoxicillin may interact with Pulse Frequency
There are 20 known major drug interactions with Amoxicillin.
Common Amoxicillin Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Amoxicillin.
Aclidinium
Minor
Amoxicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Amoxicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Amoxicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Amoxicillin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Amoxicillin Toxicity & Overdose RiskOverdosing on phenytoin may cause blood in the urine, reduced urine output, abdominal pain, kidney failure, vomiting, diarrhea, rash, hyperactivity, and drowsiness. Treatment for phenytoin overdose includes supportive care and may involve inducing vomiting or dialysis.

Amoxicillin Novel Uses: Which Conditions Have a Clinical Trial Featuring Amoxicillin?

60 active trials are currently being conducted to investigate the potential of Amoxicillin in alleviating Urinary Tract Infections, ENT infections and Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Bacterial Infections
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting
Duodenal Ulcer
0 Actively Recruiting
Bronchitis
2 Actively Recruiting
Not Applicable
ABDIC protocol
0 Actively Recruiting
ear, nose, and throat infections
0 Actively Recruiting
Community Acquired Pneumonia (CAP)
5 Actively Recruiting
Not Applicable, Phase 1, Phase 3
Sinusitis
2 Actively Recruiting
Not Applicable
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Peptic Ulcer With H. Pylori Infection
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Gonorrhea
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Otitis
3 Actively Recruiting
Not Applicable

Patient Q&A Section about amoxicillin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amoxicillin used for?

"Amoxicillin is an antibiotic that belongs to the group of penicillins. It is used to treat bacterial infections like chest infections, pneumonia, and dental abscesses. It can also be used in combination with other antibiotics and medications to treat stomach ulcers."

Answered by AI

What is the most common side effect of amoxicillin?

"Side effects of amoxicillin are typically mild and can include gastrointestinal issues such as an upset stomach and diarrhea, as well as a headache, rash, abnormal taste, and vaginal yeast infection. Some less common side effects that have been recorded include allergic reactions, breathing problems, and seizures."

Answered by AI

How many days should I take amoxicillin 500mg?

"The text is saying that amoxicillin is given for 5-10 days or until the infection clears. People who have recurrent ear infections are more likely to get amoxicillin/clavulanate because bacteria can become resistant to amoxicillin."

Answered by AI

What infections does amoxicillin treat?

"Amoxicillin is an antibiotic that is used to fight off infection by bacteria. Amoxicillin is commonly used to treat infections in the ear, nose, throat, skin, or urinary tract. It is also used to treat bronchitis and pneumonia."

Answered by AI

Clinical Trials for Amoxicillin

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Amoxicillin clinical trials? We made a collection of clinical trials featuring Amoxicillin, we think they might fit your search criteria.Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered Amoxicillin clinical trials? We made a collection of clinical trials featuring Amoxicillin, we think they might fit your search criteria.Go to Trials
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Amoxicillin clinical trials? We made a collection of clinical trials featuring Amoxicillin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security